Evidence map›Paper›PMID 42825062›Full record

ArticleACS omega2026

Fine-Tuning DeepSeek-OCR‑2 for Molecular Structure Recognition.

Haocheng Tang, Xingyu Dang, Junmei Wang

Abstract read
In one paragraph

Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Haocheng TangSchool of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, United States.ORCID https://orcid.org/0009-0001-5702-2847
Xingyu DangDepartment of Computer Science, Princeton University, Princeton, New Jersey 08540, United States.
Junmei WangSchool of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, United States.ORCID https://orcid.org/0000-0002-9607-8229

Funding

New Generation of General AMBER Force Field for Biomedical ResearchR01GM147673 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WANG, JUNMEI, YANG, WEI · 2022 to 2025
$1.5M
AI-Powered Biased Ligand DesignR01GM149705 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Junmei Wang · 2023 to 2026
$1.3M
High Quality Force Field Models for Biased Ligand DesignR35GM163906 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Junmei Wang · 2026 to 2026
$109k
NIGMS NIH HHS R01 GM147673NIGMS NIH HHS R01 GM149705NIGMS NIH HHS R35 GM163906
6 · The paper itself

Abstract

Optical chemical structure recognition (OCSR) is critical for converting 2D molecular diagrams from printed literature into machine-readable formats. While vision-language models have shown promise in end-to-end OCR tasks, their direct application to OCSR remains challenging, and direct full-parameter supervised fine-tuning often fails. In this work, we adapt DeepSeek-OCR-2 for molecular optical recognition by formulating the task as an image-conditioned SMILES generation. To overcome training instabilities, we propose a two-stage progressive supervised fine-tuning strategy: starting with parameter-efficient LoRA and transitioning to selective full-parameter fine-tuning with split learning rates. We train our model on a large-scale corpus combining synthetic renderings from PubChem and realistic patent images from USPTO-MOL to improve the coverage and robustness. Our fine-tuned model, MolSeek-OCR, demonstrates competitive capabilities, achieving exact-match accuracies comparable to those of the best-performing image-to-sequence model. However, it remains inferior to state-of-the-art image-to-graph models. Exploratory post-training shows mixed results: ReFT provides small benchmark-dependent gains, whereas GSPO does not yield stable improvement and can collapse under extended optimization.

Identifiers

PMID42825062
PMCPMC13629064

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.